Question to the Department for Business, Energy and Industrial Strategy:

To ask Her Majesty's Government what assessment they have made of the progress of trials of each of the COVID-19 vaccines for which they have placed orders; and when they expect to take delivery of the first doses of those vaccines.

The UK Government has secured early access to 407 million vaccine doses through agreements with seven separate vaccine developers. The Government is working closely with vaccine developers to monitor progress of clinical trials.

• The Pfizer/BioNTech vaccine was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and this vaccine is already being deployed in the UK.
• The Oxford/AstraZeneca vaccine was approved by the MHRA and this vaccine is already being deployed in the UK.
• The Moderna vaccine was approved by the MHRA. Supplies of this vaccine will begin to be delivered to the UK from the spring once Moderna expands its production capability.
• The Janssen vaccine is currently in phase 3 clinical trials. If clinical trials prove the vaccine to be safe and effective, supplies of the vaccine could start to be delivered to the UK in the second half of 2021.
• The Novavax vaccine is currently in phase 3 clinical trials. If clinical trials prove the vaccine to be safe and effective, supplies of the vaccine could start to be delivered to the UK in the second half of 2021.
• The GlaxoSmithKline/SanofiPasteur vaccine is currently in phase 1/2 clinical trials. Deliveries of this vaccine are being discussed with the developer and dependent upon the vaccine being found to be safe and effective.
• The Valneva vaccine is currently in phase 1/2 clinical trials. If clinical trials prove the vaccine to be safe and effective, supplies of the vaccine could be made available to the UK by the end of 2021.